Artiva grants COO Bush 135K options, 45K RSUs

Artiva Biotherapeutics granted option and RSU awards to its chief operating and legal officer, increasing her direct equity holdings.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that officer Jennifer Bush, who serves as COO, CLO and Compliance Officer, received equity awards on September 9, 2026. She was granted options to buy 135,000 shares of common stock at an exercise price of $10.79 per share, expiring September 8, 2036, and a 45,000-share restricted stock unit award. Following these awards, she directly holds 374,529 shares of common stock, and the option begins vesting in equal monthly installments from September 8, 2026 over four years. No Rule 10b5-1 plan is reported for these awards.

Insider Trade Summary

Grant/Award: 180,000 shares

Grant/Award 2 txns

Insider Bush Jennifer

Role COO, CLO, Compliance Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy) F2	135,000	$0.00	$0.00
Grant/Award	Common Stock F1	45,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 135,000 contracts (Direct); Common Stock — 374,529 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
2. F2. Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

Key Figures

Stock options granted: 135,000 options Option exercise price: $10.79 per share Option expiration date: September 8, 2036 +3 more

6 metrics

Stock options granted 135,000 options Options on common stock granted to Jennifer Bush on September 9, 2026

Option exercise price $10.79 per share Exercise price of options granted on September 9, 2026

Option expiration date September 8, 2036 Expiration of options granted to Jennifer Bush

Restricted stock units granted 45,000 shares Restricted stock unit award under the 2024 Equity Incentive Plan

Common shares held after award 374,529 shares Direct common stock holdings of Jennifer Bush after RSU grant

Option vesting rate 1/48th monthly over four years Vesting schedule starting September 8, 2026

Key Terms

restricted stock unit, Equity Incentive Plan, vest in equal monthly installments

3 terms

restricted stock unit financial

"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Equity Incentive Plan financial

"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vest in equal monthly installments financial

"Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Artiva Biotherapeutics (ARTV) grant to Jennifer Bush on September 9, 2026?

Artiva Biotherapeutics granted Jennifer Bush options to purchase 135,000 shares of common stock at $10.79 per share, expiring on September 8, 2036, and a 45,000-share restricted stock unit award on September 9, 2026.

How many ARTV shares does Jennifer Bush hold after the reported Form 4 transactions?

After the reported grants, Jennifer Bush directly holds 374,529 shares of Artiva Biotherapeutics common stock, as disclosed in the Form 4 filing for the restricted stock unit award dated September 9, 2026.

What is the vesting schedule for Jennifer Bush’s new stock options at Artiva Biotherapeutics (ARTV)?

Beginning on September 8, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four-year period, according to the footnote describing the option award.

Under which plan were Jennifer Bush’s new Artiva Biotherapeutics (ARTV) RSUs granted?

The 45,000-share restricted stock unit award was granted under Artiva Biotherapeutics’ 2024 Equity Incentive Plan, as stated in the footnote to the common stock award transaction.

Was Jennifer Bush’s September 2026 Form 4 activity under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with the September 9, 2026 equity awards to Jennifer Bush.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 06:36 PM Accepted by SEC EDGAR 09/11/2026 - 06:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bush Jennifer

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO, CLO, Compliance Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2026		A		45,000(1)	A	$0	374,529	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$10.79	09/09/2026		A		135,000		(2)	09/08/2036	Common Stock	135,000	$0	135,000	D

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

2. Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

	/s/ Jennifer Bush	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)